drugset / Trial / NCT06008795
BLOCK-SAH - PPF-Block for Post-SAH Headache
Phase 2
Recruiting
195 enrolled
University of Florida
Massachusetts General Hospital · collabNational Institute of Neurological Disorders and Stroke (NINDS) · collabNew York University · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injections with 20mg ropivacaine + 4mg dexamethasone (active, PPF-block) compared to saline (placebo) for headache in survivors of aneurysmal subarachnoid hemorrhage (SAH), while monitoring intracranial arterial mean flow velocities with transcranial Doppler (TCD) peri-intervention (intervention = PPF-injections: active or placebo)
Timeline
- Start
- 2023-12-17
- Primary completion
- 2027-01-15
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 4 mg | Other |
| Subject | Ropivacaine | Other / unclassified | 20 mg | Other |